N/A
Manufactured by Chattem, Inc.
44,826 FDA adverse event reports analyzed
Last updated: 2026-04-14
LEVOCETIRIZINE DIHYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Chattem, Inc.. The most commonly reported adverse reactions for LEVOCETIRIZINE DIHYDROCHLORIDE include DRUG INEFFECTIVE, SOMNOLENCE, FATIGUE, HEADACHE, PRURITUS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LEVOCETIRIZINE DIHYDROCHLORIDE.
Out of 22,799 classified reports for LEVOCETIRIZINE DIHYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 44,826 FDA FAERS reports that mention LEVOCETIRIZINE DIHYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, SOMNOLENCE, FATIGUE, HEADACHE, PRURITUS, NAUSEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Chattem, Inc. in connection with LEVOCETIRIZINE DIHYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.
Explore other medications manufactured by Chattem, Inc. and compare their safety profiles:
The following drugs share commonly reported adverse reactions with LEVOCETIRIZINE DIHYDROCHLORIDE: